All Work

Chris Lange

Huge Cyber Monday Sales at Sears

Sears could stand for a turnaround, and Cyber Monday could very well be the time with all the deals that Sears is offering.

Chris Lange · 11 years ago

Massive Cyber Monday Sales at Macy’s

Macy's is a staple among the major retailers in the United States, and like many others it is throwing out all the stops for Cyber Monday.

Chris Lange · 11 years ago

4 Key FDA Decisions Expected By Year End

Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk involved, as…

Chris Lange · 11 years ago

Short Sellers Continue to Back Off Major Semiconductors

The short interest data have come out for the November 13 settlement date. It is important to note that semiconductor trends are considered to be leading indicators of technology and broader electronics demand. On…

Chris Lange · 11 years ago

Albertsons Gears Up for IPO

Albertsons filed an amended S-1 form with the SEC as it prepares for its IPO.

Chris Lange · 11 years ago

Dollar Tree Trips Over Bottom Line on Earnings

Dollar Tree, Inc. (NASDAQ: DLTR) reported its fiscal third-quarter financial results before the markets opened on Tuesday. The company had $0.49 in earnings per share (EPS) on $4.95 billion in revenue compared to consensus…

Chris Lange · 11 years ago

Palo Alto Networks Fails to Impress With Guidance

Palo Alto Networks, Inc. (NYSE: PANW) reported its fiscal first quarter financial results after the markets closed on Monday. The company had $0.35 in earnings per share (EPS) on $297.2 million in revenue compared…

Chris Lange · 11 years ago

What to Expect From Dollar Tree Earnings

Dollar Tree, Inc. (NASDAQ: DLTR) is set to report its fiscal third quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters call for $0.53 in earnings per share…

Chris Lange · 11 years ago

Can-Fite Soars on Positive Phase 2 Developments

Biotech company Can-Fite announced development of its drug candidate CF102, which is currently in phase 2 trials for liver cancer, will be expanded into treatment for non-alcoholic steatohepatitis.

Chris Lange · 11 years ago